

Michael A Weber

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6465083/michael-a-weber-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

202
papers

15,539
citations

54
h-index

123
g-index

250
ext. papers

18,107
ext. citations

6.9
avg, IF

6.06
L-index

#	Paper	IF	Citations
202	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 12	8.7	0
201	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. <i>Circulation</i> , 2022 , 145, 847-863	16.7	3
200	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.. <i>Lancet, The</i> , 2022 , 399, 1401-1410	40	11
199	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial.. <i>Hypertension</i> , 2022 , 101161	8.5	1
198	Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. <i>American Journal of Hypertension</i> , 2021 , 34, 531-539	2.3	
197	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. <i>EuroIntervention</i> , 2021 , 16, e1496-e1502	3.1	5
196	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2021 ,	2.6	3
195	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2909-2919	15.1	21
194	Treating hypertension: who speaks for the patient?. <i>Journal of Human Hypertension</i> , 2021 , 35, 1057-1058	2.6	
193	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. <i>Lancet, The</i> , 2021 , 397, 2476-2486	40	47
192	Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021 , 39, 1742-1767	1.9	15
191	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021 , 110, 725-731	6.1	7
190	Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine Infusion Catheter. <i>Cardiovascular Revascularization Medicine</i> , 2021 , 24, 77-86	1.6	0
189	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. <i>Blood Pressure</i> , 2021 , 30, 90-97	1.7	2
188	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. <i>Blood Pressure</i> , 2021 , 30, 82-89	1.7	1
187	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , 2021 , 39, 1602-1610	1.9	0
186	Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO Study. <i>Hypertension</i> , 2021 , 77, 529-536	8.5	6

185	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , 2021 , 39, 766-774	1.9	2
184	The World Hypertension League becomes a partner of the Journal of Human Hypertension. <i>Journal of Human Hypertension</i> , 2021 , 35, 821-822	2.6	
183	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, 416-426	2.7	5
182	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1028-1038	15.1	5
181	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , 2021 , 23, 100818	1.8	1
180	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. <i>American Heart Journal</i> , 2021 , 233, 22-30	4.9	4
179	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010075	6	3
178	Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model. <i>American Journal of Nephrology</i> , 2021 , 52, 429-434	4.6	0
177	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2922-2933	5	19
176	Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers. <i>Hypertension</i> , 2020 , 75, 1584-1592	8.5	6
175	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. <i>Lancet, The</i> , 2020 , 395, 1444-1451	40	166
174	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach to randomised controlled trials. <i>BMJ Open</i> , 2020 , 10, e002302	6.1	15
173	The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 461-470	5.70	23
172	Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. <i>Hypertension</i> , 2020 , 76, 1410-1417	8.5	18
171	Systemic hemodynamic atherothrombotic syndrome (SHATS) - Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 22-32	8.5	27
170	Methodological and Regulatory Considerations for Updated Guidance on the Pressor Effects of Drugs. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 1473-1476	1.2	2
169	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , 2020 , 41, 231-238	9.5	16
168	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. <i>European Heart Journal</i> , 2019 , 40, 2006-2017	9.5	145

167	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019 ,	16.7	58
166	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019 , 40, 2032-2043	9.5	23
165	Emergence of Home Blood Pressure-Guided Management of Hypertension Based on Global Evidence. <i>Hypertension</i> , 2019 , HYPERTENSIONAHA11912630	8.5	36
164	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. <i>Hypertension</i> , 2019 , HYPERTENSIONAHA11913081	8.5	12
163	Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1095-1105	5	36
162	Abstract 109: Changes in Plasma Renin Activity After Renal Denervation in the Spyral Htn-Off Med Trial. <i>Hypertension</i> , 2019 , 74,	8.5	1
161	The Accuracy in Measurement of Blood Pressure (AIM-BP) collaborative: Background and rationale. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 1780-1783	2.3	10
160	São Paulo call to action for the prevention and control of high blood pressure: 2020. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 1744-1752	2.3	25
159	Nocturnal blood pressure measured by home devices: evidence and perspective for clinical application. <i>Journal of Hypertension</i> , 2019 , 37, 905-916	1.9	45
158	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , 2019 , 40, 743-751	9.5	44
157	Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 356-365	2.3	6
156	Global Implications of Blood Pressure Thresholds and Targets: Guideline Conversations From the World Hypertension League. <i>Hypertension</i> , 2018 , 71, 985-987	8.5	10
155	Cardiovascular Safety of the β -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1084-1091	2.9	11
154	A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 947-956	1.9	2
153	Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	5
152	Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. <i>European Heart Journal</i> , 2018 , 39, 2243-2251	9.5	109
151	A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. <i>Blood Pressure Monitoring</i> , 2018 , 23, 153-163	1.3	4
150	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. <i>American Heart Journal</i> , 2018 , 195, 115-129	4.9	39

149	Blood pressure measurement in special populations and circumstances. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 1122-1127	2.3	14
148	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>European Heart Journal</i> , 2018 , 39, 3105-3114	9.5	54
147	Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Circulation</i> , 2018 , 138, 1602-1604	16.7	28
146	A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2018 , 19, 1470320318795000	0	0
145	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018 , 391, 2346-2355	40	358
144	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet, The</i> , 2018 , 391, 2335-2345	40	301
143	May Measurement Month 2017: an analysis of blood pressure screening results worldwide. <i>The Lancet Global Health</i> , 2018 , 6, e736-e743	13.6	166
142	The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association. <i>European Heart Journal</i> , 2017 , 38, 712-719	9.5	52
141	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. <i>Current Problems in Cardiology</i> , 2017 , 42, 198-225	17.1	13
140	Intensive treatment of hypertension to a SBP . <i>Evidence-Based Medicine</i> , 2017 , 22, 30		
139	Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 695-701	2.3	6
138	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017 , 389, 2226-2237	40	171
137	Olmесartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 1309-1318	2.3	2
136	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017 , 390, 2160-2170	40	406
135	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. <i>European Heart Journal</i> , 2017 , 38, 93-100	9.5	79
134	2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 1082-1085	2.3	13
133	Is It Time to Reappraise Blood Pressure Thresholds and Targets? A Statement From the International Society of Hypertension-A Global Perspective. <i>Hypertension</i> , 2016 , 68, 266-8	8.5	11
132	Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. <i>Blood Pressure</i> , 2016 , 25, 93-103	1.7	68

131	Hypertension: Cardiovascular benefits of lowering blood pressure. <i>Nature Reviews Nephrology</i> , 2016 , 12, 202-4	14.9	14
130	Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 211-220	18.1	143
129	Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. <i>European Heart Journal</i> , 2016 , 37, 955-64	9.5	68
128	No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. <i>Blood Pressure</i> , 2016 , 25, 83-92	1.7	41
127	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , 2016 , 171, 82-91	4.9	104
126	High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 711-7	2.3	24
125	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 299-307	2.3	20
124	Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 141-6	2.3	3
123	MY APPROACH to the patient with hard-to-control hypertension. <i>Trends in Cardiovascular Medicine</i> , 2015 , 25, 755-6	6.9	
122	Optimum antihypertensive therapy: does adiposity matter?. <i>Lancet, The</i> , 2015 , 385, 834-6	40	1
121	A Tribute to Dr John H. Laragh. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 495-8	2.3	1
120	Remembering Dr Marvin Moser. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 1-4	2.3	
119	Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 845-54		13
118	β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 872-81	5.8	62
117	Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. <i>Lancet, The</i> , 2014 , 383, 1889-98	40	52
116	Recently published hypertension guidelines of the JNC 8 panelists, the American Society of Hypertension/International Society of Hypertension and other major organizations: introduction to a focus issue of the Journal of Clinical Hypertension. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 241-5	2.3	9
115	Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 14-26	2.3	588
114	Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. <i>Blood Pressure Monitoring</i> , 2014 , 19, 90-7	1.3	8

113	Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. <i>Journal of Hypertension</i> , 2014 , 32, 3-15	1.9	396
112	John Laragh and the renin thesis: creating a paradigm. <i>American Journal of Hypertension</i> , 2014 , 27, 1008-9,3		
111	Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. <i>American Journal of Medicine</i> , 2013 , 126, 501-8	2.4	40
110	Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. <i>American Journal of Cardiology</i> , 2013 , 112, 255-9	3	18
109	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. <i>Lancet, The</i> , 2013 , 381, 537-45	4.0	109
108	Obesity, blood pressure, and cardiovascular outcomes - AuthorsQepl. <i>Lancet, The</i> , 2013 , 381, 1982-3	4.0	
107	Progression of Chronic Kidney Disease in Patients with Diabetes: Implications for Practice. <i>Endocrine Practice</i> , 2013 , 19, 8-13	3.2	
106	Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 284-92	2.3	37
105	Blood pressure effects of combined β -blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 588-92	2.3	18
104	Predictors of systolic BP . <i>Blood Pressure</i> , 2012 , 21, 82-7	1.7	3
103	Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). <i>Journal of the American College of Cardiology</i> , 2012 , 59, 74-83	15.1	126
102	Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. <i>American Journal of Medicine</i> , 2012 , 125, 1229.e1-1229.e10	2.4	59
101	Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. <i>Endocrine Practice</i> , 2012 , 18, 1029-37	3.2	2
100	The Physician Payments Sunshine Act: A Setback for Medical Progress. <i>Drug Information Journal</i> , 2012 , 46, 292-293		1
99	Renal outcomes in hypertensive Black patients at high cardiovascular risk. <i>Kidney International</i> , 2012 , 81, 568-76	9.9	26
98	Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. <i>Hypertension</i> , 2012 , 60, 310-8	8.5	51
97	Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. <i>Journal of Hypertension</i> , 2012 , 30, 2213-22	1.9	21
96	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2037-114	15.1	325

95	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society		100
94	The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. <i>Journal of Clinical Hypertension</i> , 2011 , <i>13</i> , 81-82	2.3	111
93	Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. <i>Hypertension</i> , 2011 , <i>57</i> , 413-20	8.5	167
92	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation</i> , 2011 , <i>123</i> , 2434-506	16.7	255
91	Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. <i>Hypertension</i> , 2011 , <i>57</i> , 174-9	8.5	48
90	Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. <i>Hypertension</i> , 2010 , <i>56</i> , 824-30	8.5	141
89	Cardiovascular events during differing hypertension therapies in patients with diabetes. <i>Journal of the American College of Cardiology</i> , 2010 , <i>56</i> , 77-85	15.1	172
88	Combination therapy in hypertension. <i>Journal of the American Society of Hypertension</i> , 2010 , <i>4</i> , 90-8		134
87	Telmisartan in high-risk cardiovascular patients. <i>American Journal of Cardiology</i> , 2010 , <i>105</i> , 36A-43A	3	2
86	Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. <i>Journal of Clinical Hypertension</i> , 2010 , <i>12</i> , 678-86	2.3	20
85	Treatment of patients with hypertension and arthritis pain: new concepts. <i>American Journal of Medicine</i> , 2009 , <i>122</i> , S16-22	2.4	10
84	A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009 , <i>374</i> , 1423-31	40	222
83	Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?. <i>Journal of Hypertension</i> , 2009 , <i>27</i> , S9-14	1.9	8
82	Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. <i>Journal of Hypertension</i> , 2009 , <i>27</i> , 1360-9	1.9	242
81	The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. <i>Journal of the Cardiometabolic Syndrome</i> , 2008 , <i>3</i> , 229-33		9
80	Beta-blockers in the treatment of hypertension: new data, new directions. <i>Journal of Clinical Hypertension</i> , 2008 , <i>10</i> , 234-8	2.3	7
79	Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. <i>New England Journal of Medicine</i> , 2008 , <i>359</i> , 2417-28	59.2	1518
78	Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. <i>Blood Pressure</i> , 2008 , <i>17</i> , 7-17	1.7	41

77	Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. <i>Blood Pressure</i> , 2008 , 17, 260-9	1.7	7
76	Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. <i>Blood Pressure</i> , 2007 , 16, 13-9	1.7	59
75	New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>American Journal of Cardiology</i> , 2007 , 100, 45J-52J	3	11
74	Secondary analysis of the VALUE trial: intriguing new questions. <i>Current Hypertension Reports</i> , 2007 , 9, 261-3	4.7	
73	Exceptional early blood pressure control rates: the ACCOMPLISH trial. <i>Blood Pressure</i> , 2007 , 16, 80-6	1.7	97
72	Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 760-9	2.3	68
71	The Metabolic Syndrome 2007 , 678-690		
70	Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement. <i>Reviews in Cardiovascular Medicine</i> , 2007 , 8 Suppl 2, S1-6	3.9	2
69	Controlled-release carvedilol in the treatment of essential hypertension. <i>American Journal of Cardiology</i> , 2006 , 98, 32L-38L	3	27
68	The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. <i>Hypertension</i> , 2006 , 48, 385-91	8.5	114
67	Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. <i>American Heart Journal</i> , 2006 , 151, 176-84	4.9	55
66	An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 241-50; quiz 251-2	2.3	1
65	Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 840-9	2.3	29
64	Hypertension treatment and implications of recent cardiovascular outcome trials. <i>Journal of Hypertension</i> , 2006 , 24, S37-44	1.9	11
63	Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. <i>Journal of Hypertension</i> , 2006 , 24, 2163-8	1.9	110
62	Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?. <i>Reviews in Cardiovascular Medicine</i> , 2006 , 7, 45-54	3.9	29
61	The role of the new beta-blockers in treating cardiovascular disease. <i>American Journal of Hypertension</i> , 2005 , 18, 169S-176S	2.3	86
60	Managing the patient at risk for a second stroke. <i>Journal of Hypertension</i> , 2005 , 23, S41-7	1.9	6

59	Clinical trials report. Vascular effects beyond blood pressure: the CAMELOT study. <i>Current Hypertension Reports</i> , 2005 , 7, 235-7	4-7	
58	Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes. <i>Managed Care Interface</i> , 2005 , 18, 47-54		6
57	Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trial. <i>The American Journal of Geriatric Cardiology</i> , 2004 , 13, 131-6		4
56	Angiotensin II receptor blockers in older patients. <i>The American Journal of Geriatric Cardiology</i> , 2004 , 13, 197-205; quiz 206-7		7
55	Clinical trials report. Consequences of new-onset diabetes during the treatment of hypertension. <i>Current Hypertension Reports</i> , 2004 , 6, 291-2	4-7	3
54	Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. <i>American Journal of Hypertension</i> , 2004 , 17, 37-42	2-3	49
53	Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. <i>American Journal of Hypertension</i> , 2004 , 17, 252-9	2-3	119
52	Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. <i>American Journal of Hypertension</i> , 2004 , 17, 793-801	2-3	69
51	Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 168-74	2-3	37
50	Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. <i>Lancet, The</i> , 2004 , 363, 2022-31	40	2112
49	Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. <i>Lancet, The</i> , 2004 , 363, 2049-51	40	472
48	Circadian variations in cardiovascular disease: chronotherapeutic approaches to the management of hypertension. <i>Reviews in Cardiovascular Medicine</i> , 2004 , 5, 148-55	3-9	8
47	Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 2073-82	27.4	517
46	Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?. <i>Blood Pressure Monitoring</i> , 2003 , 8, 215-22	1-3	1
45	The telmisartan programme of research to show Telmisartan End-organ protection (PROTECTION) programme. <i>Journal of Hypertension</i> , 2003 , 21, S37-46	1-9	32
44	A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. <i>Current Hypertension Reports</i> , 2003 , 5, 319-21	4-7	
43	The ALLHAT report: a case of information and misinformation. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 9-13	2-3	41
42	The JNC 7 report: challenges and dilemmas in writing guidelines. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 282-6	2-3	

41	Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 322-9	2.3	11
40	Creating a combination antihypertensive regimen: what does the research show?. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 12-20	2.3	19
39	Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. <i>American Journal of Hypertension</i> , 2003 , 16, 460-6	2.3	17
38	Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003 , 4, 62-73	3	7
37	Outcomes of treating hypertension in the elderly: a short commentary on current issues. <i>The American Journal of Geriatric Cardiology</i> , 2003 , 12, 14-8		8
36	The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?. <i>American Journal of Cardiology</i> , 2002 , 89, 27A-33A	3	46
35	Calcium channel antagonists in the treatment of hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2002 , 2, 415-31	4	15
34	Clinical implications of aldosterone blockade. <i>American Heart Journal</i> , 2002 , 144, S12-8	4.9	26
33	The effect of antihypertensive drugs on vascular compliance. <i>Current Hypertension Reports</i> , 2001 , 3, 297-304	4.9	27
32	One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. <i>Hypertension</i> , 2001 , 38, 1118-23	8.5	23
31	Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 169-74	15.1	94
30	Arterial compliance abnormalities in isolated systolic hypertension. <i>American Journal of Hypertension</i> , 2001 , 14, 1007-11	2.3	54
29	Differing roles of body mass and the renin-angiotensin system in mediating the hypertension syndrome. <i>American Journal of Nephrology</i> , 2000 , 20, 169-74	4.6	9
28	Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. <i>Contemporary Clinical Trials</i> , 1998 , 19, 370-90		75
27	Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. <i>Circulation</i> , 1997 , 96, 308-15	16.7	1410
26	The Therapeutic Implications of Left Ventricular Hypertrophy in the Hypertensive Patient. <i>American Journal of Therapeutics</i> , 1995 , 2, 972-977	1	2
25	Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 346-52	6.1	10
24	Lead-induced hypertension: possible role of endothelial factors. <i>American Journal of Hypertension</i> , 1993 , 6, 723-9	2.3	94

23	Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. <i>American Journal of Hypertension</i> , 1992 , 5, 247S-251S	2.3	74
22	Heredity and hypertension: impact on metabolic characteristics. <i>American Heart Journal</i> , 1992 , 124, 435-440	4.0	37
21	Overview of Fosinopril. <i>Drug Investigation</i> , 1991 , 3, 3-11		10
20	Sympathetic nervous system and hypertension. Therapeutic perspectives. <i>American Journal of Hypertension</i> , 1989 , 2, 147S-152S	2.3	7
19	Clinical pharmacology of centrally acting antihypertensive agents. <i>Journal of Clinical Pharmacology</i> , 1989 , 29, 598-602	2.9	6
18	Characterization of Antihypertensive Therapy by Whole-Day Blood Pressure Monitoring. <i>JAMA - Journal of the American Medical Association</i> , 1988 , 259, 3281	27.4	57
17	Blood pressure monitoring for assessing the duration of action of antihypertensive treatment. <i>Journal of Clinical Pharmacology</i> , 1987 , 27, 751-5	2.9	11
16	Effect of the calcium channel blocker nitrendipine on left ventricular mass in patients with hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 40, 679-85	6.1	29
15	The circadian blood pressure pattern in ambulatory normal subjects. <i>American Journal of Cardiology</i> , 1984 , 54, 115-9	3	113
14	The combined alpha- and beta-adrenergic blocker labetalol and propranolol in the treatment of high blood pressure: similarities and differences. <i>Journal of Clinical Pharmacology</i> , 1984 , 24, 103-12	2.9	13
13	Cardiac muscle mass during vasodilation therapy of hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 727-32	6.1	67
12	Vasoconstrictor effects of aldosterone in isolated vascular tissue. <i>Clinical and Experimental Hypertension</i> , 1982 , 4, 1583-91		8
11	Renin subgroups in essential hypertension. <i>Clinical and Experimental Hypertension</i> , 1982 , 4, 1817-34		6
10	The role of aldosterone in the response to treatment of primary hypertension. <i>Clinical and Experimental Hypertension</i> , 1982 , 4, 1923-34		
9	Mineralocorticoids in Essential and Secondary Hypertension Introduction to the Symposium. <i>Clinical and Experimental Hypertension</i> , 1982 , 4, 1447-1450		
8	Differential effects of diuresis and beta-adrenoreceptor blockade during angiotensin-converting enzyme inhibition in patients with severe hypertension. <i>Journal of Clinical Pharmacology</i> , 1982 , 22, 179-86 ⁹	2.9	11
7	Changes in ventricular septal thickness during diuretic therapy. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 32, 283-8	6.1	86
6	A vasodilator that avoids renin stimulation and fluid retention: antihypertensive treatment with trimazosin. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 31, 572-8	6.1	12

5	Centrally acting antihypertensive agents: a comparison of lofexidine with clonidine. <i>Journal of Clinical Pharmacology</i> , 1981 , 21, 65-71	2.9	9
4	Low-dose diuretic and beta adrenoceptor blocker in essential hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 28, 149-58	6.1	15
3	The abrupt discontinuation of antihypertensive treatment. <i>Journal of Clinical Pharmacology</i> , 1979 , 19, 476-86	2.9	34
2	The possible importance of aldosterone as well as renin in the long-term antihypertensive action of propranolol. <i>American Journal of Medicine</i> , 1978 , 64, 187-92	2.4	32
1	Disparate patterns of aldosterone response during diuretic treatment of hypertension. <i>Annals of Internal Medicine</i> , 1977 , 87, 558-63	8	51